S&P/ASX 200 morning report – A2M, MSB & QBE shares in focus
Drew Meredith, CFP
December 21, 2020
The S&P/ASX 200 (INDEXASX:XJO) is set to open higher on
Mesoblast Ltd (ASX:MSB) is a leader in providing allogeneic (off the shelf) cellular medicines. It owns a portfolio of late-stage product candidates with three product candidates in Phase 3 trials, being acute graft versus host disease, chronic heart failure and chronic low back pain due to degenerative disc disease. The company has facilities in Melbourne, New York, Singapore and Texas and is listed on the ASX and the NASDAQ.
The S&P/ASX 200 (INDEXASX:XJO) is set to open higher on
The Mesoblast Limited (ASX:MSB) share price has plunged 43% after
The Mesoblast Limited (ASX:MSB) share price has sunk around 10%
The Mesoblast Limited (ASX: MSB) share price could soar today
The share price of biotechnology company Imugene Limited (ASX: IMU)
The S&P/ASX 200 (INDEXASX:XJO) is tipped to open higher on
The Mesoblast Limited (ASX:MSB) share price is going nuts this
The Mesoblast Limited (ASX:MSB) share price is surging this morning
It has been an absolute rollercoaster ride for anyone who
Want to level-up your analytical skills and investing insights but don’t know where to start? Join 50,000 Australian investors on our mailing list and we’ll send you our favourite podcasts, courses, resources and investment articles every Sunday morning. Grab a coffee and let Owen and the team bring you the best insights.
Here you go: A $50,000 per year passive income special report
Join more 50,000 Australian investors who read our weekly investing newsletter and we’ll send you our passive income investing report right now.
Simply enter your email address and we’ll send it to you. No tricks. Unsubscribe anytime.
Unsubscribe anytime. Read our Terms, Financial Services Guide, Privacy Policy. We’ll never sell your email address. Our company is Australian owned.